Genmab

	24/5 20:20 af nohope	I´ll take your word for it - and abstain from watching it.
	24/5 19:55 af E L	omg, this video lol, JNJ marketing really lost it ;-) ; if you weren't scared to get lung cancer yet; you will be after watching this (link)
	24/5 16:56 af Bulder	Da Helge skrev det, var den i +1,81%
	24/5 16:48 af Helge Larsen/PI-redaktør	Bulder...Den gønne farve er blevet mørkere +1.81% . :-)
	24/5 16:18 af Helge Larsen/PI-redaktør	Langers Skarpe: Ny fremgangsperiode for clean energy og health care? (link)
	24/5 16:07 af E L	But any good take-over rumour is always welcome ;-)
	24/5 16:06 af E L	It may be a bit annoying for us, bit it is most likely just JNJ’s marketing team trying to make them look as good as possible…without malicious intent towards Genmab…
	24/5 16:06 af E L	In JNJ's defence; these articles are very unlikely to be written by the scientists that know all the ins and outs of this development trajectory...
	24/5 15:58 af Bulder	Ahr nu er du fedtet Helge. Nasdaq oner 1%. Gmab 1,5%
	24/5 15:54 af Helge Larsen/PI-redaktør	Lysegrønt! ;-)
	24/5 15:40 af Bulder	Us lægger ud i det grønne område.
	24/5 15:38 af Skyggen	:-)
	24/5 15:37 af Skyggen	Hehe that was a good one Bulder, det kunne også være at der er kommet en afgørelse på voldgift sagen og den ikke helt gik JNJ’s vej og de nu er ved at blive enige om en offenligørelse
	24/5 15:33 af Bulder	If Usmani is right that duobody is Janssen’s then it must be in the very near future :-)
	24/5 15:32 af Helge Larsen/PI-redaktør	Sorry. That was a bad joke.
	24/5 15:31 af Helge Larsen/PI-redaktør	Or calculate to do so in the near future with an offer Genmab can not refuse. :-D
	24/5 15:28 af Bulder	Maybe they already bought genmab, but just kept it as a secret ;-)
	24/5 15:26 af Helge Larsen/PI-redaktør	In a way, it seems dishonorable and childish.
	24/5 15:24 af Helge Larsen/PI-redaktør	It's a weird thing. Makes absolutely no sense.
	24/5 15:19 af Bulder	None of these articles mention genmab. Usmani is talking about Janssen’s duobody-platform.
	24/5 15:05 af Helge Larsen/PI-redaktør	" second study, known as MonumenTAL-1, found that talquetamab, a bispecific antibody targeting CD3 and a new target, GPRC5D, shrank the tumors of 70% of 30 myeloma patients who had tried a median of six prior treatments".
	24/5 15:02 af Helge Larsen/PI-redaktør	"One study, dubbed MajesTEC-1, tested teclistamab, a bispecific antibody targeting BCMA and CD3, in 40 patients with multiple myeloma whose cancer had returned after a median of five other treatments or had not responded to treatment in the first place. The treatment shrank the tumors of 65% of those patients and eliminated them in 40%".
	24/5 14:42 af E L	ASCO: J&J's subcutaneous bispecifics tackles multiple myeloma in phase 1 (link)
	24/5 14:41 af Helge Larsen/PI-redaktør	GENMAB - Video "Phase I study of teclistamab" (link)

	24/5 14:34 af Helge Larsen/PI-redaktør	Fantastisk. Thanks E L.
	24/5 14:21 af E L	Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma (link)
	24/5 14:14 af E L	Janssen's Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma (link)
	24/5 05:30 af Helge Larsen/PI-redaktør	God morgen. :-)
	23/5 22:49 af kkjoel	Men denneher MÅ IKKE-regel er da fantastisk: "Be too similar to any other FDA-designated nonproprietary name suffix". DER kan jeg godt være bange for at vmjw minder lidt for meget om fihj..
	23/5 22:41 af kkjoel	Men pyt.. det skal nok gå alligevel.. ;-)
	23/5 22:40 af kkjoel	Ikke helt sikkert på jeg fanger hvad "wmjw svarer til fihj" skal betyde.. andet end at de tilgrundliggende orddannelsesregler er de samme...
	23/5 22:29 af Solsen	JNJ kan ikke holde til at smide $bn efter $bn til Genmab....
	23/5 22:18 af Bulder	vmjw svarer så til hyaluronidase-fihj, altså fihj
	23/5 21:50 af royal	JnJ havde chancen i ca kurs 200.
	23/5 21:41 af Solsen	Jeg tænkte det samme som skyggen 16:17 ;-)
	23/5 20:36 af bibob	Ja, han er utrættelig. :-). Så selvfølgelig også tak til ham. ;-). Har han fået Duracell batterier af dig Helge. ? :-D
	23/5 20:08 af Helge Larsen/PI-redaktør	Bibob..Det er utrættelige E L som har lagt den ud via link til Janssens opslag på Twitter. Tak til ham. :-)
	23/5 19:15 af bibob	Tak for artiklen Helge. Bare synd at opfinderen af stoffet ikke er nævnt med en stavelse. Det er dog på trods af Genmab at J&J kan skumme fløden. Sær opførsel. :-(
	23/5 18:08 af Helge Larsen/PI-redaktør	(link)
	23/5 17:40 af Helge Larsen/PI-redaktør	Enig Stroka. Jeg lægger artiklen op i debatten.
	23/5 17:36 af Stroka	Citat fra: Roland Knoblauch, M.D., Ph.D., Executive Medical Director, Clinical Oncology, Janssen R&D
	23/5 17:35 af Stroka	Indholdet i artiklen er da helt vildt positivt ud over at Genmab ikke nævnes: F.eks. “I believe we’re just seeing the beginning of what this drug can potentially do." :-)
	23/5 16:17 af Skyggen	:-)
	23/5 16:17 af Skyggen	Det kunne være JNJ ikke vil skubbe for meget til Genmab kursen med valideringen af duobody teknologien, hvis JNJ’s regnedrengene er ved at regne på et købs tilbud
	23/5 14:57 af Helge Larsen/PI-redaktør	Fra Janssens artikel: Dr. Knoblauch is hopeful that the drug will prove to be an effective treatment for other types of cancer, as well. “There are several other types of tumors we can explore where one of the same genes that our bispecific binds to is overexpressed,” he says. “I’m looking forward to seeing if there is potential for this drug to help patients with other types of cancers, too.” (link)
	23/5 14:41 af Stroka	ØU i dag: "Genmab - Hold Aktuel kurs: 2389,00 Genmab er steget siden kursbunden i 1902 i begyndelsen af marts. Men stigningen har endnu ikke elimineret det forudgående fald, og kursen har heller ikke passeret modstanden ved 2450".
	23/5 14:19 af Sukkeralf	Godt fundet kkjoel
	23/5 14:14 af kkjoel	•Look similar to or be capable of being mistaken for the name of a currently marketed product (e.g., should not increase the risk of confusion or medical errors with the product and/or other products in the clinical setting)•Look similar to or otherwise connote the name of the license holder•Be too similar to any other FDA-designated nonproprietary name suffix"
	23/5 14:14 af kkjoel	Og det MÅ IKKE: "•Be false or misleading, such as by making misrepresentations with respect to safety or efficacy•Include numerals and other symbols aside from the hyphen attaching the suffix to the core name•Include abbreviations commonly used in clinical practice in a manner that may lead the suffix to be misinterpreted as another element on the prescription or order•Contain or suggest any drug substance name or core name..
	23/5 14:13 af kkjoel	Fra FDA-dok: Det SKAL "•Be unique•Be devoid of meaning •Be four lowercase letters of which at least three are distinct •Be nonproprietary•Be attached to the core name with a hyphen•Be free of legal barriers that would restrict its usage"